TISSIUM is a clinical and commercial-stage MedTech company founded in 2013 that develops fully biosynthetic, biomorphic, programmable elastomeric polymers for atraumatic tissue repair and tissue reconstruction. The company’s first commercial product, COAPTIUM® CONNECT, received FDA marketing authorization and TISSIUM has entered the U.S. commercial market. Its diversified pipeline includes one commercial product and six products in development across three core verticals: atraumatic sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. TISSIUM pairs its polymer solutions with specialized delivery and activation devices designed to optimize procedure consistency and usability. The company is based in Paris and Cambridge and operates a manufacturing site in Roncq, France. Recent financing provides capital to support commercial rollout, advance multiple clinical programs and continue expanding its proprietary biomorphic polymer platform.

Total raised

$233M

Funding rounds

11

Latest round

Series D

Latest activity

Jun 2026